HIMS · NYSE · STOCK
Hims & Hers Health (HIMS) Stock Analysis
$30.91
52W $13.74 – $65.30
52/100
$6.90B
-50.7
2.43
Is HIMS Bullish or Bearish?
Mixed.
Innellis AI committee rates Hims & Hers Health (HIMS) Watch with a composite score of 52/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.82 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.18 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.80) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 28.0% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 13.7x prices in significant intangible value — Value
- ROE of only -30.0% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 1.80 adds balance-sheet risk to the value case — Value
- 2 consecutive earnings misses -- execution concerns — Growth
- Price trading above the upper Bollinger Band -- stretched — Technical
- High leverage (debt-to-equity 1.80) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 87%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.7x prices in significant intangible value
Growth Analyst
bullish
63
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 28.0% YoY -- genuine top-line momentum
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
− Price trading above the upper Bollinger Band -- stretched
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.80) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 52.2 to 52.2.
- New bearish signals: 1 appeared.
Analyst-level changes:
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
63.0
Neutral
MACD Histogram
0.154
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$26.73
Resistance
$31.85
Bollinger %B
1.05
Above Upper Band
Price vs Moving Averages
EMA 9
$29.44
Above
EMA 21
$29.23
Above
EMA 50
$29.43
Above
EMA 200
$30.46
Above
Fundamental Analysis
Valuation
63
Growth
29
Profitability
65
Financial Health
6
Cash Flow
70
Valuation
P/E Ratio
-50.7×
P/B Ratio
22.11×
PEG Ratio
1.21
Dividend Yield
0.00%
52W High
$65.30
52W Low
$13.74
Quality & Growth
ROE
2373.0%
ROA
595.7%
Gross Margin
6468.2%
Operating Margin
-359.4%
Revenue Growth YoY
—
Debt / Equity
4.77
AI Fundamental Assessment
P/E ratio of -50.7 (inexpensive relative to a 15-40x range); Price-to-book of 22.1x; PEG ratio of 1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 23.7%; Return on assets of 6.0%; Net margin of -5.5%; Gross margin of 64.7%; Current ratio of 0.93 (tight short-term liquidity); Debt-to-equity of 4.77; Free cash flow per share is positive (0.39); Most recent quarter missed estimates by 2487.4%; 2 consecutive earnings misses; EPS growth accelerating (-337.5% -> -94.7% QoQ); Average YoY EPS growth of -317.6%; Analyst estimates falling over recent quarters
Get the Full HIMS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →